10X Genomics Hits New 52-Week High of $28.17, Reflecting Strong Growth

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 28.17 on May 28, 2026. This achievement marks a notable increase from its 52-week low of USD 8.81, reflecting a robust performance over the past year. In the last year, 10X Genomics has demonstrated a performance increase of 26.19%, slightly trailing behind the S&P 500's performance of 28.45%. The company's market capitalization stands at USD 2,132 million, positioning it firmly within the small-cap category. Despite being loss-making, the company has a price-to-book ratio of 2.68, indicating its valuation relative to its net assets. The debt-to-equity ratio of -0.64 suggests a unique financial structure, while the return on equity stands at -10.80%. With no dividend yield reported, 10X Genomics continues to focus on its growth trajectory within the competitive biotechnology landscape.